How real-world evidence supports oncology drug development
RWE in oncology must stand up to regulatory, HTA, and access scrutiny—requiring decision‑grade, multimodal, globally relevant data.
Real-world evidence generation for better, faster decisions
BC Platforms’ clinical and post-launch evidence generation solution helps life sciences teams move from fragmented real-world data (RWD) to timely, decision-ready real-world evidence (RWE) for clinical, regulatory, payer, medical, and commercial decisions. We help you build the right evidence network, create bespoke datasets, and analyze securely in your own trusted research environment.
Built around your evidence priorities
Your research needs are specific. Your evidence strategy should be, too.
We help you configure the right evidence network for a single study or a broader evidence-generation program across one or more therapeutic areas — connecting priority markets, patient populations, data sources, your target sites, and BC Platforms’ global partner network, which includes:
187M+
patients accessible
35+
countries represented
>90%
patients ex-US
150+
data partnerships
Generate decision-ready evidence at scale
BC Platforms brings together the data access, federation, harmonization, analytics, and expertise needed to turn complex RWD into evidence life sciences teams can use across the product lifecycle. The result is a scalable evidence-generation model that supports single studies — and broader programs — spanning multiple therapeutic areas and use cases.
Access rich, federated data for deeper insights
Access global, granular patient-level data through a secure federated model that brings disparate datasets together for comprehensive analytics and better-informed decisions.
Work with bespoke datasets, not static snapshots
We harmonize, anonymize, and master data from different sites and sources so your teams can work with cohesive, comparable datasets built around the clinical, regulatory, payer, or commercial question at hand.
Treatment patterns and outcomes
Compare treatment patterns, outcomes, and care pathways across markets.
Patient cohorts
Define patient cohorts and sub-populations with greater precision.
Retro- and prospective
Support retrospective and prospective studies from R&D through market uptake.
Reusable evidence
Reuse evidence as new questions, indications, and milestones emerge.
Power advanced analytics and AI at scale
Use BC Mosaic as your secure analytics environment to analyze bespoke BC Platforms datasets, your own data, or both — with scalable compute, advanced analytics, and AI in one trusted workspace.
Analyze harmonized datasets — ours and yours — with built-in capabilities
Scale compute-intensive workflows across large, complex datasets
Leverage validated applications that integrate easily with BC Mosaic
Bring your own AI models, tools, apps, and data sources
Expertise to help you move faster
When you need additional capacity or specialized expertise, we can help keep evidence programs moving — from scientific strategy and study support to data architecture, integration, analytics workflows, and AI enablement.
Move from complexity to evidence
Wherever you are in the product lifecycle, the right evidence foundation can help your teams move faster, answer higher-stakes questions, and make confident decisions as your program evolves.
Explore more evidence-generation insights
Read more
Choosing a real-world evidence platform: what actually matters
Most RWE platforms can generate analyses. Few deliver results that can be validated, reused, and applied with confidence.
BC Platforms partners with Flower Labs to enable federated machine learning across trusted research environments
Federated learning with the Flower Framework is available within BC Platforms’ trusted research environments.
Common questions about clinical and post-launch evidence generation
Real-world evidence is difficult to generate because patient-level data is often fragmented across sites, markets, and systems, with different governance requirements, formats, quality levels, and access timelines. Life sciences teams need a secure way to bring disparate real-world data together, harmonize it, and analyze it consistently to support clinical, regulatory, payer, medical, and commercial decisions.
BC Platforms provides an end-to-end RWE solution that helps life sciences teams move beyond fragmented data access to secure, scalable evidence generation. We build custom site and data partner networks across countries, create bespoke datasets from multi-modal patient-level RWD, and deliver harmonized, analysis-ready data into BC Mosaic, our trusted research environment. From there, teams can apply BC Platforms analytics capabilities, validated partner applications, their own AI models and tools, or additional data sources to support retrospective and prospective research across the product lifecycle — from R&D through post-launch, market access, and uptake.
This approach is supported by BC Platforms’ global data partner network, which includes 187M+ accessible patients, 150+ data partners, 35+ countries, and more than 90% non-US patients.
Traditional RWD providers often focus on access to existing datasets or centralized data aggregation. BC Platforms helps life sciences teams build custom evidence networks, create bespoke datasets, and securely analyze harmonized patient-level data across countries, sites, and sources. By combining global data access, federated analytics, BC Mosaic trusted research environments, and expert services, we support evidence generation for both single studies and broader lifecycle programs.
Yes. BC Platforms can master and harmonize bespoke BC Platforms datasets, customer-owned data, and third-party sources into a cohesive, analysis-ready dataset. In BC Mosaic, our trusted research environment (TRE), teams can analyze that combined dataset using built-in capabilities, validated applications, or their own AI models, tools, apps, and data sources.
Yes. BC Platforms supports both retrospective and prospective real-world evidence studies by helping life sciences teams access, harmonize, and analyze patient-level RWD through custom evidence networks, bespoke datasets, and BC Mosaic, our trusted research environment (TRE). This helps teams reuse and extend evidence foundations as new questions, indications, markets, and milestones emerge.